These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26721505)

  • 21. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.
    Sarnes E; Crofford L; Watson M; Dennis G; Kan H; Bass D
    Clin Ther; 2011 Oct; 33(10):1413-32. PubMed ID: 21999885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
    Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
    Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
    Borker R
    J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost analysis of adverse events associated with non-small cell lung cancer management in France.
    Chouaid C; Loirat D; Clay E; Millier A; Godard C; Fannan A; Lévy-Bachelot L; Angevin E
    Clinicoecon Outcomes Res; 2017; 9():443-449. PubMed ID: 28794648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic burden of haematological adverse effects in cancer patients: a systematic review.
    Liou SY; Stephens JM; Carpiuc KT; Feng W; Botteman MF; Hay JW
    Clin Drug Investig; 2007; 27(6):381-96. PubMed ID: 17506589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.
    Fourcade RO; Benedict A; Black LK; Stokes ME; Alcaraz A; Castro R
    BJU Int; 2010 Jan; 105(1):49-56. PubMed ID: 20132102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review.
    Juniper M; Le TK; Mladsi D
    Expert Opin Pharmacother; 2009 Nov; 10(16):2581-92. PubMed ID: 19874246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic evaluation of perioperative adverse events associated with spinal surgery.
    Hellsten EK; Hanbidge MA; Manos AN; Lewis SJ; Massicotte EM; Fehlings MG; Coyte PC; Rampersaud YR
    Spine J; 2013 Jan; 13(1):44-53. PubMed ID: 23384882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct health care costs of hospital admissions due to adverse events in The Netherlands.
    Magdelijns FJ; Stassen PM; Stehouwer CD; Pijpers E
    Eur J Public Health; 2014 Dec; 24(6):1028-33. PubMed ID: 24699427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic melanoma: optimizing outcomes by managing dermatologic toxicities associated with novel therapies.
    Claveau J; Ho V; Petrella T
    Skin Therapy Lett; 2014; 19(2):1-4. PubMed ID: 24740745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The economic burden of prostate cancer.
    Roehrborn CG; Black LK
    BJU Int; 2011 Sep; 108(6):806-13. PubMed ID: 21884356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Years of life lost due to metastatic melanoma in 12 countries.
    Thiam A; Zhao Z; Quinn C; Barber B
    J Med Econ; 2016; 19(3):259-64. PubMed ID: 26531249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
    Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
    J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.
    Niraula S; Amir E; Vera-Badillo F; Seruga B; Ocana A; Tannock IF
    J Clin Oncol; 2014 Nov; 32(32):3634-42. PubMed ID: 25267757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
    Ghate SR; Li Z; Tang J; Nakasato AR
    Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
    Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
    Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health care expenditures in nine industrialized countries, 1960-76.
    Simanis JG; Coleman JR
    Soc Secur Bull; 1980 Jan; 43(1):3-8. PubMed ID: 6769168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists.
    Clegg JP; Guest JF; Lehman A; Smith AF
    Ophthalmic Epidemiol; 2006 Aug; 13(4):263-74. PubMed ID: 16877285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.